Short Interest: A Reversal for Angiodynamics Incorporated (NASDAQ:ANGO) Is Not Near. The Stock Has Rise in Shorts

November 24, 2016 - By Peter Erickson   ·   0 Comments

Short Interest: A Reversal for Angiodynamics Incorporated (NASDAQ:ANGO) Is Not Near. The Stock Has Rise in Shorts

The stock of Angiodynamics Incorporated (NASDAQ:ANGO) registered an increase of 8.3% in short interest. ANGO’s total short interest was 743,500 shares in November as published by FINRA. Its up 8.3% from 686,500 shares, reported previously. With 406,600 shares average volume, it will take short sellers 2 days to cover their ANGO’s short positions. The short interest to Angiodynamics Incorporated’s float is 3.17%. The stock increased 1.14% or $0.19 on November 23, hitting $16.88. About 142,236 shares traded hands. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 35.69% since April 22, 2016 and is uptrending. It has outperformed by 30.28% the S&P500.

AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The company has a market cap of $623.63 million. The Company’s devices are used in minimally invasive, image-guided procedures. It currently has negative earnings. The Firm offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery.

Insitutional Activity: The institutional sentiment increased to 2.61 in 2016 Q2. Its up 0.74, from 1.87 in 2016Q1. The ratio increased, as 11 funds sold all AngioDynamics, Inc. shares owned while 20 reduced positions. 10 funds bought stakes while 48 increased positions. They now own 24.22 million shares or 1.02% less from 24.47 million shares in 2016Q1.
State Of New Jersey Common Pension Fund D last reported 65,000 shares in the company. State Board Of Administration Of Florida Retirement has 0% invested in the company for 35,168 shares. Blackrock Mgmt Ltd Limited Liability Company has 124,572 shares for 0% of their US portfolio. Blackrock, a New York-based fund reported 6,207 shares. Moreover, Pub Sector Pension Board has 0% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 18,124 shares. Wells Fargo And Mn holds 626,223 shares or 0% of its portfolio. Dimensional Fund Advsrs Lp holds 0.02% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO) for 2.97 million shares. The Manitoba – Canada-based Great West Life Assurance Co Can has invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Arrowstreet Ltd Partnership holds 107,095 shares or 0.01% of its portfolio. Tfs Limited accumulated 0.11% or 42,097 shares. Northern has 975,955 shares for 0% of their US portfolio. First Quadrant Limited Partnership Ca has 8,700 shares for 0% of their US portfolio. Deutsche National Bank Ag has 0% invested in the company for 67,034 shares. Arizona State Retirement holds 0% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO) for 13,696 shares. Tower Research Ltd (Trc) has invested 0% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO).

Insider Transactions: Since August 5, 2016, the stock had 0 buys, and 4 insider sales for $131.24 million net activity. $32.79 million worth of shares were sold by Avista Capital Partners GP – LLC on Friday, November 18. Burgstahler David F had sold 2.25 million shares worth $32.90M.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

Out of 6 analysts covering AngioDynamics (NASDAQ:ANGO), 2 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 33% are positive. AngioDynamics has been the topic of 8 analyst reports since July 24, 2015 according to StockzIntelligence Inc. Canaccord Genuity maintained it with “Buy” rating and $14.5 target price in Friday, January 8 report. The company was upgraded on Monday, August 31 by Zacks. Cantor Fitzgerald initiated the shares of ANGO in a report on Friday, November 4 with “Buy” rating. KeyBanc Capital Markets initiated the shares of ANGO in a report on Friday, July 24 with “Overweight” rating. The rating was initiated by Sidoti with “Neutral” on Wednesday, September 23. The firm earned “Hold” rating on Tuesday, April 5 by Canaccord Genuity. The firm earned “Neutral” rating on Friday, April 8 by Piper Jaffray. The firm has “Mkt Perform” rating by Raymond James given on Tuesday, November 10.

ANGO Company Profile

AngioDynamics, Inc., incorporated on July 30, 1992, designs, makes and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures. The Firm offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery.

More news for AngioDynamics, Inc. (NASDAQ:ANGO) were recently published by: Equitiesfocus.com, which released: “AngioDynamics, Inc. (NASDAQ:ANGO) Short-Term Price Target At $18.10” on November 22, 2016. Globenewswire.com‘s article titled: “AngioDynamics Appoints Michael C. Greiner as New Chief Financial Officer” and published on July 25, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Peter Erickson


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>